(Q53248280)

English

The use of quality-adjusted life-years in cost-effectiveness studies.

scientific article published in May 2006

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

title

The use of quality-adjusted life-years in cost-effectiveness studies. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

author name string

Sculpher M

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

publication date

1 May 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

published in

Allergy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

volume

61

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

page(s)

527-530

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

cites work

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01053.X

retrieved

21 January 2018

Health economic guidelines--similarities, differences and some implications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01053.X

retrieved

21 January 2018

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01053.X

retrieved

21 January 2018

Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01053.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1398-9995.2006.01053.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

PubMed publication ID

16629779

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16629779

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16629779

ResearchGate publication ID

7150467

0 references

(Q53248280)

The use of quality-adjusted life-years in cost-effectiveness studies.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)